Overview

A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies

Status:
Completed
Trial end date:
2018-08-21
Target enrollment:
Participant gender:
Summary
Two part study to evaluate the safety, tolerability, pharmacokinetics, and efficacy (in Part 2 only) of KRP203 in patients undergoing allogeneic hemopoietic stem cell transplant for hematological malignancies
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals